Rich Handler, chief executive of Jefferies Financial Group, handed out some advice to the 361 global analyst and associate ...

Luspatercept showed similar efficacy and safety in real-world settings as observed in the MEDALIST trial for LR-MDS patients post-ESA failure. Transfusion independence was achieved in 44.3% of ...

KINGSTON, JAMAICA – Staff of Medical Disposables and Supplies (MDS), along with family, on Friday joined forces with the Kingston Public Hospital (KPH) to refresh the Outpatient Department ...

This mechanism also promotes the disassembly of pre-formed NLRP3 inflammasomes, targeting a key inflammatory pathway implicated in bone marrow dysfunction in myelodysplastic syndromes (MDS).

This is the third indication for Reblozyl (luspatercept), which is already used to treat anaemia in patients with rare blood disorder beta thalassaemia and as a second-line therapy for MDS ...

This study is building a record of information about a group of bone marrow disorders called myelodysplastic syndromes (MDS). The bone marrow is the body’s blood cell factory. In myelodysplastic ...

MDS are a group of closely related blood cancers in which there is ineffective production of healthy red blood cells, white blood cells, and platelets. This can lead to anaemia and frequent or ...

The myelodysplastic syndromes (MDS) are disorders of the haematopoietic stem cells in the bone marrow, that result in a decreased production of blood cells. MDS mainly affects patients aged 70 and ...

Panelists discuss how splice modifiers work by enhancing protein production from the SMN2 gene, with risdiplam (Evrysdi) being an oral daily medication and nusinersen (Spinraza) being administered ...